drugset
Drugs / Elranatamab
last change 5 days ago re-read 2 minutes ago

Elranatamab

also known as PF-06863135 · Elra · Elranatamab-bcmm · Elrexfio · RN-613

Monoclonal antibody targets TNFRSF17

Developed for
plasma cell myeloma · refractory plasma cell neoplasm · AL amyloidosis · plasmablastic lymphoma · smoldering plasma cell myeloma
Investigated by
Pfizer · Massachusetts General Hospital · M.D. Anderson Cancer Center · SCRI Development Innovations, LLC · Anne Louise Tølbøll Sørensen · Brigham and Women's Hospital
+24 more · Bristol-Myers Squibb · C4 Therapeutics, Inc. · Case Comprehensive Cancer Center · David Avigan · Genentech, Inc. · H. Lee Moffitt Cancer Center and Research Institute · Intergroupe Francophone du Myelome · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · McMaster University · Memorial Sloan Kettering Cancer Center · Nantes University Hospital · National Comprehensive Cancer Network · Ontario Clinical Oncology Group (OCOG) · PETHEMA Foundation · Sanofi · Stichting European Myeloma Network · Thomas Lund · University of California, San Diego · University of Illinois at Chicago · University of Miami · Vejle Hospital · Washington University School of Medicine · YOUNGIL KOH · coMMit, Myeloma Trials, Innovated

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ELREXFIO — 2025-07-10 fda.gov ↗
Approved · conditional EU (EMA) Elrexfio — 2023-12-07 europa.eu ↗
Approved US (FDA) ELREXFIO — 2023-08-14 fda.gov ↗

Trials 42 · a red edge is where a trial was stopped

today
US approved 2023
EU approved 2023
NCT07474961 · Ph 4 NCT07647432 · Ph 2/3 NCT07637578 · Ph 2 NCT07247097 · Ph 2 NCT07524634 · Ph 2 NCT07382739 · Ph 2 NCT07454382 · Ph 2 NCT07280013 · Ph 1 NCT06997081 · Ph 2 NCT06832865 · Ph 2 NCT06974786 · Ph 2 NCT06918002 · Ph 3 NCT06947083 · Ph 2 NCT06931704 · Ph 2 NCT06421675 · Ph 2 NCT06799026 · Ph 1 NCT06015542 · Ph 2 NCT06483100 · Ph 2 NCT06711705 · Ph 2 NCT06645678 · Ph 1/2 NCT06569147 · Ph 1/2 NCT06207799 · Ph 2 NCT06183489 · Ph 2 NCT06138275 · Ph 2 NCT06121843 · Ph 1 NCT06215118 · Ph 1 NCT06152575 · Ph 3 NCT06282978 · Ph 2 NCT06057402 · Ph 4 NCT05927571 · Ph 1 NCT05675449 · Ph 1 NCT05623020 · Ph 3 NCT05317416 · Ph 3 NCT05228470 · Ph 2 NCT05090566 · Ph 2 NCT05014412 · Ph 2 NCT05020236 · Ph 3 NCT04798586 · Ph 1 NCT04649359 · Ph 2 NCT03269136 · Ph 1
20182019202020212022202320242025202620272028202920302031203220332034203520362037
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT07280013 Feb 2026 → Dec 2028 expected plasma cell myeloma C4 Therapeutics, Inc. Recruiting No outcome recorded
Phase 1 NCT06799026 Jan 2025 → Sep 2028 expected plasma cell myeloma David Avigan Recruiting No outcome recorded
Phase 1 NCT06121843 Feb 2024 → Aug 2028 expected plasma cell myeloma Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Recruiting No outcome recorded
Phase 1 NCT06215118 Feb 2024 → Apr 2027 expected plasma cell myeloma Pfizer Recruiting No outcome recorded
Phase 1 NCT05927571 Aug 2023 → Jul 2027 expected refractory plasma cell neoplasm Genentech, Inc. Recruiting No outcome recorded
Phase 1 NCT05675449 Dec 2022 → Jul 2025 overdue plasma cell myeloma Pfizer Active not recruiting No outcome recorded
Phase 1 NCT04798586 Mar 2021 → May 2022 refractory plasma cell neoplasm Pfizer Completed No outcome recorded
Phase 1 NCT03269136 Nov 2017 → Jan 2024 plasma cell myeloma Pfizer Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT06645678 Nov 2024 → Oct 2026 expected refractory plasma cell neoplasm YOUNGIL KOH Recruiting No outcome recorded
Phase 1/2 NCT06569147 Nov 2024 → Sep 2027 expected AL amyloidosis Brigham and Women's Hospital Recruiting No outcome recorded
Phase 222 trials
Phase 2 NCT07247097 Aug 2026 → Dec 2030 expected plasma cell myeloma Massachusetts General Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07637578 Aug 2026 → Oct 2029 expected plasma cell myeloma SCRI Development Innovations, LLC Not yet recruiting No outcome recorded
Phase 2 NCT07524634 Jun 2026 → Jun 2031 expected AL amyloidosis Case Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07382739 Mar 2026 → Dec 2028 expected plasma cell myeloma, refractory plasma cell neoplasm M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2 NCT07454382 Feb 2026 → Aug 2029 expected plasma cell myeloma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT06997081 Sep 2025 → Sep 2030 expected plasma cell myeloma University of Miami Recruiting No outcome recorded
Phase 2 NCT06832865 Aug 2025 → Dec 2026 expected refractory plasma cell neoplasm Massachusetts General Hospital Recruiting No outcome recorded
Phase 2 NCT06974786 Aug 2025 → Nov 2032 expected plasma cell myeloma SCRI Development Innovations, LLC Recruiting No outcome recorded
Phase 2 NCT06947083 May 2025 → Apr 2029 expected plasma cell myeloma H. Lee Moffitt Cancer Center and Research Institute Recruiting No outcome recorded
Phase 2 NCT06931704 May 2025 → Nov 2030 expected plasma cell myeloma Nantes University Hospital Not yet recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT07647432 Dec 2026 → Dec 2029 expected HIV infectious disease, plasmablastic lymphoma University of Illinois at Chicago Not yet recruiting No outcome recorded
Phase 35 trials
Phase 3 NCT06918002 Jul 2025 → May 2036 expected plasma cell myeloma Intergroupe Francophone du Myelome Recruiting No outcome recorded
Phase 3 NCT06152575 Feb 2024 → Aug 2026 overdue plasma cell myeloma Pfizer Recruiting No outcome recorded
Phase 3 NCT05623020 Nov 2022 → Oct 2030 expected plasma cell myeloma Pfizer Recruiting No outcome recorded
Phase 3 NCT05317416 Mar 2022 → Aug 2027 expected plasma cell myeloma Pfizer Active not recruiting No outcome recorded
Phase 3 NCT05020236 Oct 2021 → Apr 2026 overdue plasma cell myeloma Pfizer Recruiting No outcome recorded
Phase 42 trials
Phase 4 NCT07474961 Mar 2027 → Dec 2036 expected Waldenstrom macroglobulinemia, plasma cell myeloma Anne Louise Tølbøll Sørensen Not yet recruiting No outcome recorded
Phase 4 NCT06057402 Oct 2023 → Feb 2032 expected plasma cell myeloma Pfizer Recruiting No outcome recorded
Phase not stated2 trials
— NCT05462639 — plasma cell myeloma Pfizer No longer available No outcome recorded
— NCT05238311 — plasma cell myeloma Pfizer No longer available No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06988488 Background Oct 2025 → May 2027 expected plasma cell myeloma Celgene Corporation Recruiting No outcome recorded
Phase 1/2 NCT06106945 Background Dec 2023 → Aug 2027 expected plasma cell myeloma AstraZeneca Recruiting No outcome recorded
Phase 1/2 NCT04068597 Background Aug 2019 → Mar 2027 expected T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma CellCentric Ltd. Recruiting No outcome recorded

Press releases naming this drug 9 releases

DateIssuerRelease
2026-04-29 Pfizer Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma pfizer.com ↗
2024-06-14 Pfizer ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma pfizer.com ↗
2023-12-08 Pfizer European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma pfizer.com ↗
2023-08-14 Pfizer Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma pfizer.com ↗
2023-02-22 Pfizer Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance pfizer.com ↗
2022-12-10 Pfizer Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial pfizer.com ↗
2022-11-03 Pfizer Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma pfizer.com ↗
2021-02-17 Pfizer Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma pfizer.com ↗
2020-12-07 Pfizer Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma pfizer.com ↗

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 47 sources stand behind the page.

FieldValueCited text
Known as Elranatamab “Elranatamab is a type of drug called a bispecific antibody that connects a B cell maturation antigen (BCMA), a protein on plasma cells, with CD3, a protein on T cells.” NCT07524634 ↗
43

“Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells.” PMID 37783970 ↗ Oct 2023

“Elranatamab will be dosed in 28-day cycles as follows:” NCT06483100 ↗

NCT05228470 ↗

NCT05927571 ↗

NCT06988488 ↗

NCT06997081 ↗

NCT06947083 ↗

NCT07280013 ↗

NCT05675449 ↗

NCT04649359 ↗

NCT04068597 ↗

NCT06183489 ↗

NCT06207799 ↗

NCT07647432 ↗

NCT06711705 ↗

NCT06974786 ↗

NCT07474961 ↗

NCT05238311 ↗

NCT05623020 ↗

NCT05020236 ↗

NCT07247097 ↗

NCT06152575 ↗

NCT06645678 ↗

NCT06121843 ↗

NCT05014412 ↗

NCT05317416 ↗

NCT06015542 ↗

NCT07637578 ↗

NCT07382739 ↗

NCT06832865 ↗

NCT06057402 ↗

NCT06799026 ↗

NCT06918002 ↗

NCT05462639 ↗

NCT06282978 ↗

NCT06138275 ↗

NCT06106945 ↗

NCT06421675 ↗

NCT05090566 ↗

NCT06215118 ↗

NCT04798586 ↗

NCT06569147 ↗

NCT06931704 ↗
Known as Elra “Elranatamab (Elra)” NCT07647432 ↗
Known as Elranatamab-bcmm ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454382 ↗
Known as Elrexfio “Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.” NCT06421675 ↗
Known as PF-06863135 “AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB +...” NCT05623020 ↗
8

“A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN...” NCT05014412 ↗

“The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma.” NCT04649359 ↗

“study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma.” NCT05228470 ↗

“Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)” NCT05238311 ↗

“Elranatamab (PF-06863135)” NCT04798586 ↗

“Elranatamab (PF-06863135)” NCT05462639 ↗

“Elranatamab (PF-06863135)” NCT06282978 ↗

“Elranatamab (PF-06863135)” NCT07247097 ↗
Known as RN-613 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297809 ↗
Action Deplete “The drug then activates T-cells to kill the myeloma cells.” NCT06138275 ↗
Modality Monoclonal antibody “BCMA-CD3 bispecific antibody” NCT05228470 ↗
Route Subcutaneous “patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses.” PMID 37582952 ↗ Aug 2023
Target TNFRSF17 “Tumor necrosis factor receptor superfamily member 17 binding agent” CHEMBL4297809 ↗